Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database.
Authors
David Edward Kaplan
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
David Edward Kaplan , Amie Tan , Cheryl Xiang , Fan Mu , Sarika Ogale , Sairy Hernandez , Jiayang Li , Yilu Lin , Lizheng Shi , Amit G. Singal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 446)
DOI
10.1200/JCO.2024.42.3_suppl.446
Abstract #
446
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction–associated steatotic liver disease.
First Author: Hirokazu Takahashi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
First Author: Jamie Grossman
Poster
2022 ASCO Annual Meeting
Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The therapeutic strategy for choosing lenvatinib in systemic therapy for unresectable hepatocellular carcinoma.
First Author: Kaoru Tsuchiya